DMAC
Diamedica Therapeutics Inc
NASDAQ · Biotechnology
$8.14
+0.60 (+7.96%)
Open$7.74
Previous Close$7.54
Day High$8.24
Day Low$7.58
52W High$10.42
52W Low$3.19
Volume—
Avg Volume188.4K
Market Cap423.91M
P/E Ratio—
EPS$-0.72
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
-48.9% upside
Current
$8.14
$8.14
Target
$4.16
$4.16
$2.49
$4.16 avg
$4.48
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 75.08M | 73.96M | 78.61M |
| Net Income | 7.50M | 6.55M | 6.83M |
| Profit Margin | 10.0% | 8.9% | 8.7% |
| EBITDA | 9.74M | 10.19M | 9.65M |
| Free Cash Flow | 6.22M | 6.24M | 10.05M |
| Rev Growth | +22.4% | +12.6% | +21.2% |
| Debt/Equity | 0.48 | 0.47 | 0.46 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |